All In Biotech

Free tool

FAERS Monitor: Stimufend

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761173 or its brand name (Stimufend, Pegfilgrastim-Fpgk). Reports on generic versions are filed under their own applications.

Reports

1

Serious

1

100% of reports

Hospitalization

1

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • anaemia1
  • bacterial infection1
  • diarrhoea1
  • dyspnoea1
  • lactic acidosis1
  • nausea1
  • neutropenia1
  • septic shock1

Reports by year received

View as table
YearReports
20241

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,158 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bacterial infection11127.61111.5281
lactic acidosis1649.4642.4162
septic shock1483.5478.9120
neutropenia1154.7153.938
anaemia1110.3109.827
dyspnoea137.237.19
diarrhoea132.632.57
nausea126.626.56

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.